Huayi Group discusses Q3 performance, valuation plan, and buyback strategy

Shanghai Huayi Group addressed various investor questions during its Q3 2025 earnings conference on December 19, 2025. The company confirmed that its perfluoropolyether products have been industrialized with increasing output. Additionally, it stated that its core technologies for hexafluorobutadiene (C4F6) and octafluorocyclobutane (C318) are proprietary, with a comprehensive patent layout.

Regarding its "2025 Valuation Enhancement Plan," initiated on April 22, 2025, the company noted an improvement in its A-share stock price between the announcement date and December 18, 2025. This plan encompasses business enhancement, M&A, equity incentives, employee stock ownership, cash dividends, investor relations management, strengthened information disclosure, and share buybacks/shareholder increases.

The company also confirmed plans for share buybacks, responding to investor interest by leveraging internal funds or special buyback loans. Furthermore, its controlling shareholder announced a plan on March 18, 2025, to increase its stake by up to 2% within six months, reflecting confidence in the company's long-term value.